Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio
Source: Bloomberg ·
Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.
From the source
- EnglishUnited States - Deutsch - English - Español - Français - Italiano - All languages - Afrikaans - azərbaycan - bosanski - català - Čeština - Cymraeg - Dansk - Deutsch - eesti - EnglishUnited Kingdom - EspañolEspaña - EspañolLatinoamérica - euskara - Filipino - FrançaisCanada - FrançaisFrance - Gaeilge - galego - Hrvatski - Indonesia - isiZulu - íslenska - Italiano - Kiswahili - latviešu - lietuvių - magyar - Melayu - Nederlands - norsk - o‘zbek - polski - PortuguêsBrasil - PortuguêsPortugal - română - shqip - Slovenčina - slovenščina - srpski (latinica) - Suomi - Svenska - Tiếng Việt - Türkçe - Ελληνικά - беларуская - български - кыргызча - қазақ тілі - македонски - монгол - Русский - српски - Українська - ქართული - հայերեն - עברית - اردو - العربية - فارسی - አማርኛ - नेपाली - मराठी - हिन्दी - অসমীয়া - বাংলা - ਪੰਜਾਬੀ - ગુજરાતી - ଓଡ଼ିଆ - தமிழ் - తెలుగు - ಕನ್ನಡ - മലയാളം - සිංහල - ไทย - ລາວ - မြန်မာ - ខ្មែរ - 한국어 - 日本語 - 简体中文 - 繁體中文 - 繁體中文香港 - EnglishUnited States - Deutsch -…
BestAIBroker analysis
- Finance-aware sentiment: slightly positive (+0.20 on a -1 to +1 scale).
- Event classification: OTHER.
- Market importance score: 36/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.